This area of our website is for healthcare professionals only

Please click below to declare your professional status:

YES, I am a healthcare professional  NO, I am not a healthcare professional

Our cookies

We use cookies, which are small text files, to improve your experience on our website.
You can allow or reject non essential cookies or manage them individually.

Manage cookiesAllow all

Cookie policy

Our cookies

Allow all

We use cookies, which are small text files, to improve your experience on our website. You can allow all or manage them individually.

You can find out more on our cookie page at any time.

EssentialThese cookies are needed for essential functions such as logging in and making payments. Standard cookies can't be switched off and they don't store any of your information.
AnalyticsThese cookies help us collect information such as how many people are using our site or which pages are popular to help us improve customer experience. Switching off these cookies will reduce our ability to gather information to improve the experience.
FunctionalThese cookies are related to features that make your experience better. They enable basic functions such as social media sharing. Switching off these cookies will mean that areas of our website can't work properly.
AdvertisingThese cookies help us to learn what you're interested in so we can show you relevant adverts on other websites and track the effectiveness of our advertising.
PersonalisationThese cookies help us to learn what you're interested in so we can show you relevant content.

Save preferences

HEART UK reports

Reports from HEART UK - The Cholesterol Charity

Lipoprotein(a) Taskforce -Call to Action report

The recently established Lipoprotein(a) Taskforce (Lp(a) Taskforce) has published its first  Call to Action report, encouraging greater recognition and acceptance of Lp(a) as an atherosclerotic cardiovascular disease (ASCVD) risk factor. 

Lp(a) is an independent, inherited, and causal risk factor for ASCVD, and therefore serves as a vital indicator of individual susceptibility to several related conditions, including myocardial infarctions, stroke, coronary heart disease, peripheral arterial disease, and heart failure.

Despite being a well-established risk factor for these conditions, Lp(a) is not routinely measured in clinical practice and lacks representation in appropriate UK clinical guidelines.

The Future of CVD Care in an Evolving System

As the UK recovers from the COVID-19 pandemic, we can ensure that cholesterol and familial hypercholesterolaemia remain a top health priority for the NHS and policymakers for  the benefit of patients, now and in the future. This is vital if we are to succeed in meeting the NHS Long Term Plan ambition of preventing 150,000 strokes, heart attacks and dementia cases by 2029.

The report looks at lessons learned from the pandemic and makes specific recommendations for how cholesterol and CVD diagnosis and treatment can be improved in the UK. Key recommendations include:

  • Ensure NHS Health Checks are offered to all those eligible to support primary prevention.
  • Continue to raise public awareness of CVD risk factors, especially following the replacement of Public Health England. 
  • Manage CVD throughout the treatment pathway as a family of diseases in order to ensure co-ordinated and integrated patient care.

Cardiovascular Disease Care: best practice

This report was produced for the Public Health England conference 2020 to give an overview of good practice and ways of working, following interviews and meetings conducted across the country.


 State of the Nation: Cardiovascular Disease

The report covers policy directives and strategies at a national level, the impact and opportunities that come with NHS organisational restructuring, and the ever-growing role of care and health at the community level in delivering long-term health improvement outcomes. 

The recommendations within this report are important calls to action for a wide variety of stakeholders, from those working at the highest levels of Government making decisions on NHS strategy, to those managing public health within local authorities.

Prioritising the prevention of cardiovascular disease (CVD)

HEART UK were invited by the Parliamentary Under Secretary of State for Public Health and Primary Care to submit a proposal to be included in the forthcoming Green Paper on Prevention. This paper has been developed following a cross-stakeholder roundtable discussion which included representatives from the third sector, professional organisations, NHS England, Public Health England and industry.

Identifying FH in Primary Care

In 2014, HEART UK published ‘Systematically Identifying Familial Hypercholesterolaemia (FH) in Primary Care’. The report showed how NHS Medway CCG more than doubled the number of people diagnosed with FH in the CCG by implementing two simple interventions.

Data: Helping Us Beat Cholesterol

This report was developed by HEART UK following the removal of a number of CVD indicators from the Quality and Outcomes Framework (QOF), after concerns were raised about how data relating to CVD and cholesterol is being collected. The report aims to look at current data collection practices and what barriers exist in utilising data in driving improvements in CVD patient management.